Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Diacetylmorphine hydrochloride (the active ingredient in heroin), delivered under supervision, is effective for the treatment of severe opioid use disorder. However, owing to political and regulatory barriers, it is not available in many settings around the world, which limits the options for many long-term street opioid injectors not attracted into or retained in available treatments. OBJECTIVE: To test if injectable hydromorphone hydrochloride is noninferior to injectable diacetylmorphine in reducing illicit heroin use for chronic injection opioid users after 6 months of intervention. DESIGN, SETTING, AND PARTICIPANTS: The Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) was a phase 3, double-blind, noninferiority trial. The study randomized 202 long-term street opioid injectors in Vancouver, British Columbia, Canada. Eligible participants were recruited between December 19, 2011, and December 18, 2013. Both intent-to-treat (ITT) and per-protocol (PP) analyses were conducted. INTERVENTIONS: Participants were randomly assigned to receive injectable diacetylmorphine or hydromorphone (up to 3 times daily) for 6 months under supervision. MAIN OUTCOMES AND MEASURES: Primary and coprimary efficacy outcomes were self-reported days of street heroin use (primary), days of any street-acquired opioids in the prior 30 days (noninferiority margin, 4 days), and the proportion of urinalyses positive for street heroin markers (margin, 10% of the observed rate in the diacetylmorphine group). The mean differences between diacetylmorphine and hydromorphone for the ITT and PP analyses were reported. RESULTS: The study included 202 participants; 100 randomized to receive hydromorphone and 102 to diacetylmorphine. Their mean (SD) age was 44.33 (9.63) years, and 30.7% (62 of 202) were women. Noninferiority of hydromorphone was confirmed in the PP analysis (-1.44; 90% CI, -3.22 to 0.27) for street heroin use, although the margin of 4 days was not excluded in the ITT analysis (-2.34; 90% CI, -4.14 to -0.52). Noninferiority was confirmed for any street opioids in the ITT analysis (-0.85; 90% CI, -2.97 to 1.25) and the PP analysis (-0.15; 90% CI, -2.09 to 1.76), as well as for the urinalyses (0.09; 90% CI, -0.02 to 0.19 for the ITT analysis and 0.13; 90% CI, 0.02-0.24 for the PP analysis). There were 29 SAEs considered to have some relationship with the injection medication, 5 in the hydromorphone group and 24 in the diacetylmorphine group (rate ratio, 0.21; 95% CI, 0.06-0.69). Seizures and overdoses accounted for 25 of the 29 related SAEs. CONCLUSIONS AND RELEVANCE: This study provides evidence to suggest noninferiority of injectable hydromorphone relative to diacetylmorphine for long-term opioid dependence. In jurisdictions where diacetylmorphine is currently not available or for patients in whom it is contraindicated or unsuccessful, hydromorphone could be offered as an alternative. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01447212.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Self-report among injecting drug users: A review
Darke, S. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00028-3 · Cited by 1,141
D'Agostino, R. B., Massaro, J. M., & Sullivan, L. M. (2003) · Statistics in Medicine · doi:10.1002/sim.1425 · Cited by 715
The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome
Marsden, J., Gossop, M., Stewart, D., Best, D., Farrell, M., Lehmann, P., Edwards, C., & Strang, J. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9312185711.x · Cited by 488
Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction
Oviedo-Joekes, E., Brissette, S., Marsh, D. C., Lauzon, P., Guh, D., Anis, A., & Schechter, M. T. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810635 · Cited by 375
Self-citationvan den Brink, W., Hendriks, V. M., Blanken, P., Koeter, M. W. J., van Zwieten, B. J., & van Ree, J. M. (2003) · BMJ · doi:10.1136/bmj.327.7410.310 · Cited by 347
JAMES, K. E., BLOCH, D. A., LEE, K. K., KRAEMER, H. C., & FULLER, R. K. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960715)15:13<1421::aid-sim266>3.0.co;2-h · Cited by 286
Perneger, T. V., Giner, F., del Rio, M., & Mino, A. (1998) · BMJ · doi:10.1136/bmj.317.7150.13 · Cited by 278
Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials
Kaul, S., & Diamond, G. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00011 · Cited by 272
Heroin-assisted treatment for opioid dependence: Randomised controlled trial
Haasen, C., Verthein, U., Degkwitz, P., Berger, J., Krausz, M., & Naber, D. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.026112 · Cited by 264
Self-citationStrang, J., Groshkova, T., Uchtenhagen, A., van den Brink, W., Haasen, C., Schechter, M. T., Lintzeris, N., Bell, J., Pirona, A., Oviedo-Joekes, E., et al. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.149195 · Cited by 262
Self-citationStrang, J., Metrebian, N., Lintzeris, N., Potts, L., Carnwath, T., Mayet, S., Williams, H., Zador, D., Evers, R., Groshkova, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60349-2 · Cited by 222
Differences between opioids: pharmacological, experimental, clinical and economical perspectives
Drewes, A. M., Jensen, R. D., Nielsen, L. M., Droney, J., Christrup, L. L., Arendt‐Nielsen, L., Riley, J., & Dahan, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04317.x · Cited by 208
Heroin maintenance for chronic heroin-dependent individuals
Ferri, M., Davoli, M., & Perucci, C. A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003410.pub4 · Cited by 182
Biering, K., Hjøllund, N. H., & Frydenberg, M. (2015) · Clinical Epidemiology · doi:10.2147/clep.s72247 · Cited by 180
Controlled trial of prescribed heroin in the treatment of opioid addiction
March, J. C., Oviedo‐Joekes, E., Perea‐Milla, E., & Carrasco, F. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.04.007 · Cited by 158
Self-citationDijkgraaf, M. G. W., van der Zanden, B. P., de Borgie, C. A. J. M., Blanken, P., van Ree, J. M., & van den Brink, W. (2005) · BMJ · doi:10.1136/bmj.330.7503.1297 · Cited by 157
Nosyk, B., Guh, D. P., Bansback, N. J., Oviedo‐Joekes, E., Brissette, S., Marsh, D. C., Meikleham, E., Schechter, M. T., & Anis, A. H. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.110669 · Cited by 123
Self-citationHeroin maintenance for chronic heroin-dependent individuals
Ferri, M., Davoli, M., & Perucci, C. A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003410.pub3 · Cited by 104
Beck, T., Haasen, C., Verthein, U., Walcher, S., Schuler, C., Backmund, M., Ruckes, C., & Reimer, J. (2014) · Addiction · doi:10.1111/add.12440 · Cited by 102
Non‐inferiority trials: the ‘at least as good as’ criterion
Laster, L. L., & Johnson, M. F. (2003) · Statistics in Medicine · doi:10.1002/sim.1137 · Cited by 101
Efficacy of Heroin-Assisted Treatment in Belgium: A Randomised Controlled Trial
Demaret, I., Quertemont, É., Litran, G., Magoga, C., Deblire, C., Dubois, N., Roubaix, J. D., Charlier, C., Lemaître, A., & Ansseau, M. (2015) · European Addiction Research · doi:10.1159/000369337 · Cited by 69
Strang, J., Groshkova, T., & Metrebian, N. (2012) · doi:10.2810/50141 · Cited by 61
The role of hydromorphone in cancer pain treatment: a systematic review
Pigni, A., Brunelli, C., & Caraceni, A. T. (2011) · Palliative Medicine · doi:10.1177/0269216310387962 · Cited by 48
Oviedo‐Joekes, E., Guh, D. P., Brissette, S., Marsh, D. C., Nosyk, B., Krausz, M. R., Anis, A. H., & Schechter, M. T. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.03.003 · Cited by 45
Self-citationPaterson, S., Lintzeris, N., Mitchell, T. B., Cordero, R., Nestor, L., & Strang, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01225.x · Cited by 37
Oviedo‐Joekes, E., Marchand, K., Lock, K., Macdonald, S., Guh, D. P., & Schechter, M. T. (2015) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/1747-597x-10-3 · Cited by 31
Self-citationIncidence of Hydromorphone-Induced Neuroexcitation in Hospice Patients
Kullgren, J. G., Le, V. K., & Wheeler, W. L. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0467 · Cited by 21
Hydromorphone: Evolving to Meet the Challenges of Today’s Health Care Environment
Gregory, T. B. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.027 · Cited by 18
Cited by
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Management of opioid use disorder in the USA: present status and future directions
Blanco, C., & Volkow, N. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33078-2 · Cited by 407
Fairbairn, N., Coffin, P. O., & Walley, A. Y. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.06.005 · Cited by 274
The effect of housing first on adherence to methadone maintenance treatment
Parpouchi, M., Moniruzzaman, A., Rezansoff, S. N., Russolillo, A., & Somers, J. M. (2018) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2018.03.012 · Cited by 29
George, T. P., Welsh, L., Franchuk, S. L., & Vaccarino, F. J. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437211037625 · Cited by 14
Metadata
- Authors
- Oviedo-Joekes, E., Guh, D., Brissette, S., Marchand, K., MacDonald, S., Lock, K., Harrison, S., Janmohamed, A., Anis, A. H., Krausz, M., Marsh, D. C., & Schechter, M. T.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2016-05-01
- Volume
- 73
- Issue
- 5
- Pages
- 447
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2315152690
- Cited by
- 208
- References
- 33
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.